Online,

New York,

NY,

US,

ZIP: 10007

Phone:

There’s no question that the pharmaceutical industry has been hit the hardest by COVID-19 and the many business roadblocks that have come along with it. Challenges continually arise in the pharmaceutical and life science industries regarding virtual safety of IP and due diligence practices. With the ever-evolving digital health environment, compliance practices are more important than ever. Production of the COVID-19 vaccine has brought new partnerships and M&A opportunities from non-traditional entrants which is calling for faster maturation of IP due diligence practices. Additionally, COVID-19 has caused an increase of digital health practices that is reshaping the diligence landscape for the pharmaceutical and life science industries which has created new impacts to deal-making landscapes. Best practices and standardization of due diligence amongst life science professionals is critical for continued success and compliance.

The aim of this event is to provide attendees with valuable insights and actionable strategies from cross-functional business development teams on how to execute optimal due diligence to successfully manage alliances, licensing agreements, and M&A deals. This event serves as an educational platform for industry experts responsible for due diligence, R&D, search and evaluation, external innovation, legal/IP, portfolio management, alliance management, business development and licensing, and more and will feature leadership representation from biotechs, mid-sized and large pharmaceutical, medical device and diagnostics companies.

Tickets    https://go.evvnt.com/1064499-0?pid=4528

HEALTH AND MEDICINE CONFERENCES